Adlai Nortye Doses First US Patient in Weekly Arm of Phase 1 AN9025 Trial
MT Newswires Live
Jul 16
Adlai Nortye (ANL) said Thursday it has dosed the first patient in the US in the intermittent weekly dosing arm of its phase 1 trial evaluating AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations.
The company said that intermittent dosing offers a differentiated approach and may widen the therapeutic window based on preclinical data.
Adlai said it plans to share initial phase 1 dose escalation data in the first half of next year from the continuous once-daily arm of the study, with a potential early look at the once-weekly arm.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.